發(fā)布時(shí)間：2018-06-11 22:26

  本文選題：孤兒藥 + 立法�。� 參考：《哈爾濱職業(yè)技術(shù)學(xué)院學(xué)報(bào)》2016年04期

【摘要】：我國(guó)孤兒藥立法相對(duì)滯后,研發(fā)產(chǎn)業(yè)缺乏發(fā)展動(dòng)力。在美國(guó)《孤兒藥法案》啟示下,通過(guò)對(duì)立法觀念、市場(chǎng)獨(dú)占許可制度、稅收減免政策與研發(fā)項(xiàng)目資助、市場(chǎng)內(nèi)生規(guī)律及其他國(guó)家政策等方面進(jìn)行探究,對(duì)我國(guó)孤兒藥立法之激勵(lì)性制度的成熟與完善提出相關(guān)建議。
[Abstract]:The legislation of orphan medicine in China lags behind, and the R & D industry lacks the power to develop. Under the enlightenment of the Orphan Drug Act of the United States, through the legislative concept, market exclusive licensing system, tax relief policy and R & D project funding, the laws of market endogenesis and other national policies, etc. This paper puts forward some suggestions on the maturity and perfection of the incentive system of orphan drug legislation in China.
【作者單位】： 北京理工大學(xué);
【分類(lèi)號(hào)】：D922.16;D971.2;DD912.1
，

本文編號(hào)：2006916